NCT02569515View on ClinicalTrials.gov

A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Anemia
Interventions
DRUG

Epoetin Beta

Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.

Trial Locations (4)

1233

Sofia

1431

Sofia

1504

Sofia

9002

Varna

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02569515 - A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia | Biotech Hunter | Biotech Hunter